Clinical Trial Update: Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigating CD40L-augmented tumor-infiltrating lymphocytes for advanced melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CD40L-Augmented TIL

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: RECRUITING